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SUMMARY
Altered energy metabolism is a cancer hallmark as malignant cells tailor their metabolic pathways 
to meet their energy requirements. Glucose and glutamine are the major nutrients that fuel cellular 
metabolism and the pathways utilizing these nutrients are often altered in cancer. Here, we show 
that the long ncRNA CCAT2, located at the 8q24 amplicon on cancer risk associated rs6983267 
SNP, regulates cancer metabolism in vitro and in vivo, in an allele-specific manner by binding the 
Cleavage Factor I (CFIm) complex with distinct affinities for the two subunits (CFIm25 and 
CFIm68). The CCAT2 interaction with the CFIm complex fine-tunes the alternative splicing of 
Glutaminase (GLS) by selecting the poly(A) site in intron 14 of the precursor mRNA. These 
findings uncover a complex, allele-specific regulatory mechanism of cancer metabolism 
orchestrated by alleles of a long ncRNA.
Graphical Abstract
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INTRODUCTION
Long non-coding RNAs (lncRNAs) form the largest part of the mammalian non-coding 
transcriptome (Mercer et al., 2009) and are generally expressed in a developmental-, tissue- 
or disease-stage specific manner, which makes them attractive therapeutic targets (Ling et 
al., 2013a). Although the underlying molecular mechanisms are not yet entirely understood, 
lncRNAs control gene expression at various levels including chromatin modification, 
transcriptional and post-transcriptional processing (Wilusz et al., 2009).
The revival of Warburg’s theory of cancer (Warburg, 1924), complemented with novel 
discoveries in the field, has promoted cellular metabolism as an essential molecular 
mechanism for driving malignant transformation and progression (Boroughs and 
DeBerardinis, 2015). Various studies have exposed the fine interplay between metabolic 
pathways orchestrated by protein-coding oncogenes and tumor suppressor genes (Chen and 
Russo, 2012), and more recently by ncRNAs (miRNAs and lncRNAs) (Gao et al., 2009; 
Yang et al., 2014). Glutamine, one of the essential nutrients, is deaminated by Glutaminase 
(GLS) to produce glutamate, which further serves as substrate for a variety of metabolic 
pathways (e.g. tricarboxylic cycle – TCA). Glutamine metabolism is modulated by MYC via 
miR-23a/b in prostate cancer and B cell lymphoma (Gao et al., 2009) and by NF-kB p65 
subunit also through miR-23a downregulation in leukemic cells (Rathore et al., 2012; Wang 
et al., 2010b).
Colon Cancer Associated Transcript 2 (CCAT2), a lncRNA that spans the highly conserved 
8q24 region harboring the rs6983267 SNP (Ling et al., 2013b; Redis et al., 2013), is 
associated with increased risk for various types of cancer (Tomlinson et al., 2007; Tuupanen 
et al., 2009) and is specifically overexpressed in the microsatellite stable colorectal cancer 
(CRC MSS). The two alleles of the rs6983267 SNP present in the general population have 
been shown to render distinct risks of CRC, namely the G-allele was associated with greater 
predisposition to CRC than the T-allele (Tomlinson et al., 2007). CCAT2 induces 
chromosomal instability and metastases (Ling et al., 2013b) and regulates the expression 
levels of MYC oncogene, known to coordinate multiple molecular pathways supporting cell 
proliferation, metastases and cancer metabolism (Carroll et al., 2015; Stine et al., 2015). 
However, it is not clear how the two alleles are specifically involved in the malignant 
process. In this study, we demonstrate that the lncRNA, CCAT2, modulates cellular energy 
metabolism in an allele-specific manner by interacting with the Cleavage Factor I (CFIm) 
complex to regulate the alternative splicing of GLS.
RESULTS
CCAT2 modulates energy metabolism in an allele-specific manner in vitro and in vivo
We observed an unexpected change in the color of the media of in vitro grown cells when 
modulating the expression of CCAT2 that suggested a possible shift in the energy 
metabolism consequent to CCAT2 expression. We tested this hypothesis by measuring 
metabolic parameters in HCT116 colon cancer cells that stably overexpress CCAT2 (OC1 
and OC3) (Ling et al., 2013b) versus control cells, and observed a significant and 
reproducible increase in glucose uptake, lactate secretion and oxygen consumption in the 
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CCAT2-overexpressing clones (Fig. 1A). These results were further confirmed in KM12SM 
cells with CCAT2 downregulated expression (Fig. 1B). Moreover, we explored whether 
these metabolic changes were occurring in vivo as well by injecting HCT116 CCAT2-
overexpressing cells and control cells subcutaneously into nude mice and subjecting them to 
hyperpolarized magnetic resonance imaging (HP-MRI). We detected a significant increase in 
the flux of hyperpolarized [1-13C]pyruvate to [1-13C]lactate for the xenograft tumors 
derived from the CCAT2-overexpressing cells compared to the tumors derived from control 
cells (Fig. S1A and S1B), consistent with our in vitro findings. These findings confirm that 
CCAT2 alters metabolism, boosting glycolysis and cellular respiration. The coexistence of 
increased glycolysis with increased respiration, in highly proliferative cells, translates into 
enhanced anaplerotic reactions that replenish the TCA cycle intermediates (Ward and 
Thompson, 2012). Since glutamine is the main source for replenishing the intermediates of 
the TCA cycle, we measured the intra- and extracellular glutamate concentration, as well as 
the glutamine uptake in HCT116 cells with CCAT2-overexpression and control cells. We 
found higher levels of both intra- and extracellular glutamate correspondent to higher levels 
of CCAT2 (Fig. S1C and S1D), suggesting CCAT2 is boosting glutamine metabolism 
(glutaminolysis). Surprisingly, the glutamine uptake was not significantly different between 
the three clones (Fig. S1D), implying the higher glutamate is not due to increased glutamine 
consumption. Therefore, we measured the enzymatic activity of GLS, the rate limiting 
enzyme of glutaminolysis, in the whole lysate of the same cells and detected significantly 
higher activity in the cells with increased CCAT2 expression (Fig. S1F). In addition, both 
metabolic pathways (glycolysis and glutaminolysis) have been shown to be regulated by 
many factors, including the MYC oncogene (Carroll et al., 2015; Stine et al., 2015), a target 
of CCAT2 by our previous report (Ling et al., 2013b).
We next explored whether the rs6983267 SNP influences these metabolic changes and 
assessed the glucose and glutamine uptake, oxygen consumption, lactate secretion and intra- 
and extracellular glutamate concentration in HCT116 stably overexpressing either the G-
allele or the T-allele of CCAT2 and control HCT116 cells. Interestingly, we found on one 
hand higher glucose uptake and secreted glutamate in both G- and T-allele cells compared to 
control cells, while on the other hand we observed significant differences in lactate 
secretion, oxygen consumption and intracellular glutamate production between the alleles 
(Fig. 1C and S1E). Moreover, the glutamine consumption was not significantly different 
between the clones, similar to our previous results (Fig. S1E). Consequently, we measured 
GLS enzymatic activity in these cells and observed that both CCAT2 alleles induced a 
remarkable increase in activity compared to control, but the cells overexpressing the G-allele 
displayed a significantly higher enzymatic activity compared to the T-allele overexpressing 
cells (Fig. 1D). We also analyzed by mass-spectroscopy the metabolites obtained from in 
vitro culturing of the HCT116 CCAT2 G- or T-allele and control cells and from in vivo 
xenografted tumors derived from subcutaneous injection of the same cells. We observed 
contrasting distribution patterns when performing Partial Least Squares Discriminant 
Analysis (PLS-DA) both for the in vitro (Fig. 1E) and in vivo analysis (Fig. 1F), and 
similarly for the Principal Component Analysis (PCA) analysis (Fig. S1G and S1H). We 
detected 85.04% (in vitro) and 59.55% (in vivo) of metabolic pathways upregulated by 
CCAT2 G-allele compared to the T-allele (Fig. S1I, Table S1B). We then compared the 
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pathway analysis for both datasets and identified forty common pathways for the G-allele 
and five common pathways for the T-allele (Fig. S1J). For these pathways, metabolic cluster 
distribution of differentially accumulated compounds revealed a significant overall 
enhancement of metabolic pathways related to glucose metabolism, TCA cycle and 
glutamine metabolism for the G-allele cells compared to the T-allele cells (Table S1A and 
S1B). We evaluated the expression of MYC between the HCT116 CCAT2 G- and T-allele 
cells, but did not find impressive differences, consistent with our previous findings (Ling et 
al., 2013b) (Fig. S2A). These results imply that in cells with high CCAT2 expression, MYC 
activates energy metabolism in a general fashion, however the fine-tuning of distinct 
metabolic pathways may occur through MYC-independent, but SNP-dependent 
mechanisms. We therefore decided to direct our efforts towards exploring the CCAT2 MYC-
independent mechanism of regulation.
CCAT2 regulates the expression of GLS isoforms
Our group has previously shown that CCAT2 induces chromosomal instability, a process 
highly reliant on the supply of nucleotides (Bester et al., 2011) and intimately linked to 
glutamine metabolism (Jeong et al., 2013). Further supported by the metabolic data, we 
directed our focus towards pathways metabolizing glutamine. We first assessed the protein 
expression of the two alternative splicing isoforms of GLS, KGA (glutaminase kidney 
isoform) and GAC (glutaminase isoform C) as a function of CCAT2. We used specific 
antibodies for each isoform (recognizing the distinct C-terminals) (Cassago et al., 2012) 
and/or a common antibody, recognizing the N-terminal shared by the two isoforms, 
depending on the cell line. Although the two isoforms share the same active site, GAC has a 
higher catalytic activity than KGA and therefore may be more relevant for replenishing 
intermediates of the TCA cycle (Cassago et al., 2012; Le et al., 2012). While for GAC we 
observed an increase in protein expression in the HCT116 CCAT2-overexpressing cells with 
both antibodies, for KGA the protein expression presented an inconsistent variation with 
CCAT2 upregulation (Fig. 2A, S2B and S2C). Analogously, the mRNA expression pattern 
for GAC and KGA reflected the protein expression (Fig. 2B). Moreover, downregulation of 
CCAT2 in KM12SM cells, reduced GAC protein expression with 34% and 26%, 
respectively (Fig. 2C, S2D and S2E), whereas KGA protein expression was either unaltered 
or slightly increased (Fig. 2C). Similar results were obtained when measuring the mRNA 
expression of the two isoforms in the same cellular model (Fig. S2F). Interestingly, when we 
evaluated the expression of the two isoforms in the HCT116 cells overexpressing the CCAT2 
G- or T-allele and control cells both at the mRNA and protein level, we found unanimously 
higher expression of GAC when CCAT2 G-allele is upregulated (Fig. 2D, S2G, S2H and 
S2I). However, changes in the KGA mRNA expression pattern did not concur with the 
protein expression (Fig. 2D, S2G, S2H and S2I). The discordance observed for the KGA 
isoform probably is due to the regulation by the MYC - miR-23 axis (Gao et al., 2009 - 
additional data available upon request from authors). These results alluded that CCAT2 may 
preferentially induce the splicing of the GAC isoform. To determine this we cloned the 
intron 14 of GLS precursor mRNA, known to encompass the alternative splicing site, in the 
RG6 bichromatic fluorescent reporter (Orengo et al., 2006). If the splicing machinery binds 
to the intron 14, it induces the splicing of a GFP-tagged protein, which is the equivalent of 
GAC, otherwise a dsRED-tagged protein will be produced, which is the equivalent of KGA 
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(Fig. S2J). We transfected the HCT116 control and CCAT2-overexpressing cells with the 
fluorescent reporter and determined the ratio between the expression levels of EGFP and 
dsRED fluorescence using the VECTRA automated imaging system. Although the EGFP-
tagged protein, GAC-equivalent, was predominant in all models, we observed 50% 
significantly higher EGFP/dsRED ratio in the CCAT2-overexpressing cells, corresponding 
to 50% more alternative splicing events (Fig. 2E). Similar results were obtained when cells 
were analyzed by flow cytometry (Table S2). Moreover, when we compared the alternative 
splicing events occurring in the G- and T-allele, using the RG6 reporter, we found 
significantly higher EGFP/dsRED ratio for the CCAT2 G-allele compared to the CCAT2 T-
allele (Fig. 2F, Table S2). Altogether, these data demonstrate that the CCAT2 G-allele is 
more efficient in boosting the alternative splicing of GAC isoform.
CFIm25 governs the switch between GLS splicing isoforms
To elucidate the underlying mechanism of CCAT2-induced regulation of the GLS alternative 
splicing, we introduced the MS2 tag (24 repeats) into vectors containing either the CCAT2 
G-allele or T-allele, pulled down the proteins that bind CCAT2 and analyzed them by mass 
spectrometry (Yoon et al., 2012). Pathway analysis on the Qiagen platform identified 
“Cleavage and Polyadenylation of Pre-mRNA” among the top pathways associated with the 
G-allele (Fig. S3A), with CFIm25, the small (25 kDa) subunit of CFIm encoded by the 
NUDT21 gene (Elkon et al., 2013; Yang et al., 2011) as the main protein correlated with the 
pathway. Of note, in the T-allele pull-down both CFIm25 and the larger subunit (68 kDa) of 
the CFIm complex, CFIm68 (encoded by the CPSF6 gene) were detected (CFIm68 was not 
detected in the G-allele pull-down), however for CFIm25, the area under the peak had a 1.48 
higher fold change in the G-allele compared to the T-allele (Fig. S3B). We screened the GLS 
intron 14 for potential splicing and/or alternative polyadenylation (APA) sites using ASTRA 
(Alternative Splicing and TRanscription Archives database at http://alterna.cbrc.jp/) 
(Nagasaki et al., 2006) and identified a type 2 (skipping exon) poly(A) site (Fig. S3C) (Lutz 
and Moreira, 2008) and multiple conserved binding motifs (UGUA) for CFIm25, consistent 
with a previous report mapping two poly(A) motifs within the same intron of the GLS pre-
mRNA (Tian et al., 2007). Considering that CFIm25 and the CFIm heterotetramer complex 
have been previously linked to alternative splicing (Millevoi et al., 2006; Zhou et al., 2002), 
we first downregulated NUDT21 and assessed the protein levels of GAC and KGA. We 
noticed significant decrease in GAC protein expression in both cellular models and a clear 
increase the KGA protein expression (Fig. 3A). We also measured mRNA expression for the 
two isoforms and observed a significant reduction of the GAC/KGA mRNA ratio with 
NUDT21 knockdown (Fig. 3B). In order to evaluate whether the switch in isoform 
expression is a consequence of CFIm25 binding to the UGUA sequences within intron 14 of 
GLS pre-mRNA we designed antisense oligonucleotides (ASOs) to block the binding of the 
25 kDa subunit to these motifs (Fig. 3C). Out of the four tested ASOs we could identify two 
that were able to reverse the GAC to KGA protein expression ratio similar to the specific 
downregulation of NUDT21 in HCT116 OC1 cells (Fig. 3C). This result suggested that 
binding of CFIm25 to intron 14 is responsible for inducing the preferential expression of 
GAC. To further confirm the direct interaction of CFIm25 with GLS pre-mRNA and CCAT2 
we immunoprecipitated the RNA bound to constituting proteins of the CFIm complex, 
CFIm25 and CFIm68, in HCT116 cells overexpressing either the G- or T-allele of CCAT2 
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and control cells, and measured the differences in RNA enrichment between the distinct 
pull-down lysates by real time quantitative PCR (RT-qPCR) (Fig. 3D, 3E and 3F, S3D, S3E 
and S3F). We included two lncRNAs as controls: NEAT1 was chosen to be a positive control 
as it has been previously shown to interact with the CFIm complex (Naganuma et al., 2012), 
and GAS5 was chosen as negative control, due to minimal sequence similarity with CCAT2 
(Fig S3G). When assessing the fold enrichment of GLS and CCAT2, we detected 
respectively 5.77 and 13.6 times more RNA bound to CFIm25 in the cells overexpressing 
CCAT2 G-allele compared to control cells, while in the cells overexpressing CCAT2 T-allele 
compared to control cells the fold enrichment ratios were only about half (2.95 and 6.02, 
respectively) (Fig. 3D). Moreover, comparing the fold enrichment in the G-overexpressing 
cells to the T-overexpressing cells, we observed roughly double fold enrichment in the G-
overexpressing cells for both GLS and CCAT2 (1.95 and 2.26) (Fig. 3E and 3F). The 
positive control (NEAT1) presented 6.3 fold more RNA bound to CFIm25 in the cells 
overexpressing CCAT2 G-allele compared to control cells and 2.79 fold more RNA 
enrichment in the cells overexpressing CCAT2 T-allele compared to control cells (Fig. 3D 
and S3D). The negative control (GAS5) revealed only 1.79 fold increase in the RNA bound 
to CFIm25 in the cells overexpressing CCAT2 G-allele compared to control cells and no 
difference in RNA enrichment between the overexpressing CCAT2 T-allele and control cells 
(Fig. 3D and S3E). Thus, we concluded that, overall, in the cells overexpressing CCAT2, 
there is an augmentation of interaction between CFIm25 and GLS and CCAT2, with the 
highest levels in the G-overexpressing cells. The low binding of the RNAs to the CFIm68 
was not surprising, as the main function of the protein is merely to enhance RNA binding 
and facilitate RNA looping, while the 25 kDa subunit has the leading role in binding the 
RNA via the UGUA elements (Yang Q et al, 2011) (Fig. 3E and 3F, S3D and S3E). 
Nonetheless, for our RNAs of interest we observed an increase in enrichment in the T-allele 
overexpressing cells compared to the G-allele overexpressing and control cells, suggesting 
the secondary structure of CCAT2 T-allele may ease the interaction between the 68 kDa 
subunit and RNA molecules. In addition, we confirmed these results by end point PCR both 
in the same cellular model and in KM12SM cell line, with a GT-heterozygous genotype 
(Fig. S4A and S4B). As a further validation, we expressed the RG6 bichromatic fluorescent 
reporter with the intron 14 in KM12SM cells with knockdown of NUDT21. We assessed by 
both VECTRA and FACS the ratio of EGFP to dsRED and found significantly lower (28%) 
EGFP/dsRED ratio in the cells with NUDT21 downregulation, correspondent to less splicing 
events and consequently lower expression of the GAC-equivalent (Fig. 3G and Table S2).
Alternative splicing of GLS is associated with the interaction between CCAT2 and the CFIm 
complex
We next aimed to investigate in more detail the mechanism leading to the difference in 
binding affinity of CFIm25 and CFIm68 to the distinct CCAT2 alleles. We first scanned the 
CCAT2 RNA sequence and identified two CFIm25 binding motifs surrounding the 
rs6983267, one upstream and the other downstream of the SNP. We performed secondary 
structure predictions using the RNAfold Webserver (http://rna.tbi.univie.ac.at/cgi-bin/
RNAfold.cgi) and noticed major local structural changes induced near the putative upstream 
CFIm25 binding sequence, by the single nucleotide variation, especially among the G- and 
T-alleles (Fig. S4C). Such changes may plausibly translate into distinct tertiary folds that 
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could in principle explain the binding of the G- and T-allele with different affinities. To 
further validate our results and evaluate the contribution of a single nucleotide to the 
structural changes and binding affinity, we mutated the SNP into an A or C (nucleotides 
never detected in the human population), and also deleted the 7 nucleotide region 
encompassing the SNP, which has been reported to have enhancer activity (Tuupanen et al., 
2009). We repeated the RNA-pull down assay using different vectors containing the MS2 
tags (CCAT2- G, T, A, C and DEL) and analyzed by western blot the proteins bound to 
RNAs. When CFIm25 antibody was hybridized on the blot we detected a strong band of 
approximately 64 kDa unique to the G-allele (band corresponds to the CFIm25 dimer -Fig. 
4A). When CFIm68 antibody was hybridized on the blot we distinguished bands of 
approximately 68 kDa for both the T-allele and the allele with the deleted region (Fig. 4A). 
This implied that the T-allele preferentially binds the 68 kDa subunit, but not in the region of 
the SNP. Of note, neither of the two mutated CCAT2 alleles (A and C) interacted with CFIm 
complex and interestingly, both present secondary structures different from the G- and the T-
alleles (Fig. S4C).
Additional evidence for the direct interaction between the CCAT2 G- and T-alleles with the 
CFIm complex was provided by a His6-tag pull-down assay using heterologously-expressed 
CFIm68:CFIm25 complex (His6-tagged CFIm68 subunit, Fig. 4B) incubated with in vitro 
synthesized RNAs. We detected strong affinity of the CFIm complex for the CCAT2 G-
allele, followed by moderate binding of the CCAT2 T-allele. We identified in the pull-down 
also the 600 nucleotide-long region of the GLS pre-mRNA intron 14, containing one type-2 
poly(A) site, with affinities for the protein complex corresponded to the two alleles (Fig. 
4B). This suggested that the intron 14 may interact also with CCAT2. To test this, we added 
a biotin tag to in vitro transcribed CCAT2 RNAs, combined them with the intron 14 
fragment and/or CFIm complex and pulled down the complex with Streptavidin beads. Not 
only did we confirm that CCAT2 G-allele preferentially binds CFIm25, but also that CCAT2 
interacts with the intron 14 fragment in a SNP independent fashion (Fig. 4C and S4D). To 
ensure the specificity of the interaction, we repeated the biotin RNA pull-down assay to 
include biotinylated CCAT2 C-allele as a negative control. We added also the whole intron 
14, previously used for the RG6 splicing assay, to determine if CCAT2 can interact with the 
entire region. We prepared mixes of CCAT2 (G, T and C) and the CFIm complex with and 
without the intron 14 fragment, to evaluate how it impacts the interaction between CCAT2 
and CFIm complex. We discovered that in the presence of the intron 14, CCAT2 G- and T-
allele displayed increased binding affinity to the CFIm complex, compared to the C-allele 
(Fig. 4D, S4E and Table S3). The G- and T-allele presented a remarkable specificity for the 
CFIm25 dimer in the presence of the intron 14 (both the smaller fragment and the whole 
intron) with enhanced binding to the G-allele (Fig. S4E and Table S3), supporting the 
hypothesis that the secondary structure of CCAT2 influences the interaction with the protein 
complex. In the absence of the intron, although the specificity of the interaction with the 
CFIm25 dimer is partly retained, it appeared to be revoked in the case of CFIm complex 
(Fig. 4D, S4E and Table S3). We confirmed that CCAT2 G- and T-allele can bind the whole 
intron 14 as well and aligned the CCAT2 genomic sequence with GLS genomic sequence to 
determine the extent of the interaction (Fig. S4F). We observed multiple short fragments (13 
to 18 nt) of sequence complementarity spanning the entire GLS sequence, present in both 
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introns and exons (Fig. S5A). For additional validation, we performed the His6-tag pull-
down assay using the G-, T- and C-alleles in the presence and absence of the whole intron 
14. As expected, when the intron was included in the mix, we could detect only CCAT2 G- 
and T-alleles in the pull-down lysates (Fig. S4G).
Furthermore, the same mixes of CCAT2 RNA (G/T), CFIm protein complex and intron 14 
RNA were prepared, as well as solutions of individual components, and subjected to Atomic 
Force Microscopy (AFM) for visualizing the formation of the RNA:protein:RNA quaternary 
complex (Lyubchenko et al., 2011) (Fig. 4E and 4F). Particles of substantial size were 
detected when scanning the mica surface, suggesting the formation of potential 
CCAT2:CFIm:intron14 complexes, with higher frequency for the G allele compared to the T 
allele (Fig. 4E and 4F), while the individual components (CFIm protein complex, CCAT2 
RNA and intron 14 RNA) appeared to be evidently smaller (Fig. S5B, S5C and S5D). 
Moreover, when measuring the diameter of the complexes (G-allele complex – 226.706 nm; 
T-allele complex – 182.844 nm) we found that it approximately corresponds to the sum of 
the diameter of individual components (CCAT2 – 81.865 nm; CFIm – 67.999 nm; intron 14 
– 48.360 nm).
Collectively, these findings suggested that: 1) GLS pre-mRNA impacts the interaction of 
CCAT2 with CFIm complex; 2) CCAT2 may be acting as a scaffold or assembly platform, 
promoting the selection of the poly(A) site in intron 14 of GLS pre-mRNA by directly 
binding both the pre-mRNA and the CFIm complex, and 3) the formation of the 
RNA:RNA:protein complex is dependent on the rs6983267 SNP and the secondary structure 
of CCAT2.
As an additional layer of regulation, we discovered that MYC is a transcription factor for 
NUDT21 (Data available from authors upon request).
GAC promotes metastases and cell proliferation
We proceeded with evaluating the contribution of GAC to aggressiveness of CRC. 
Considering that we have previously demonstrated that CCAT2 promotes metastases (Ling 
et al., 2013b), we first assessed the in vitro migration potential of HCT116 CCAT2-
overexpressing cells treated with either the allosteric inhibitor 968 or siRNA for GLS (Katt 
et al., 2012). We observed a reduction by half of the migration in the cells where GLS was 
either inhibited or downregulated (Fig. 5A). We next assessed the individual contribution of 
GAC to the migration, in KM12SM cells with stable downregulation of the isoform (Fig. 
S6A) and found that 60% less cells migrated when GAC expression was reduced (Fig. 5B). 
We then injected the KM12SM stable clones in the tail vein of nude mice, sacrificed the 
mice 8 weeks after injections and evaluated the in lung macro and micrometastases. 
Supporting our in vitro results, the incidence of metastases to the lung was 50% higher in the 
mice injected with the control cells (shGFP) compared to the shGAC group (Fig. 5C). 
Moreover, when we assessed the proliferation of HCT116 control and CCAT2-
overexpressing cells treated with the GLS inhibitor 968, we found that cells overexpressing 
CCAT2 were more sensitive to GLS (GAC in this case) inhibition, implying that cells with 
high CCAT2 expression are dependent on GAC for survival (Fig. 5D) (Katt et al., 2012; 
Wang et al., 2010a). Similar results were obtained when using KM12SM cells with GAC 
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downregulation compared to control cells in vitro (Fig. 5E). Additional confirmation of the 
higher dependency of the CCAT2 G-allele on GAC was provided by the colony formation 
assay for NIH3T3 cells transfected with the CCAT2-overexpressing vectors (Fig. S6B and 
S6C).
We next sought to determine if the shift in GLS isoforms expression and CFIm25 are 
responsible for the marked metabolic changes observed in cells overexpressing CCAT2. We 
therefore modulated the expression of the isoforms using the ASOs and downregulated 
NUDT21 in HCT116 CCAT2-overexpressing cell line (OC1), and measured the extracellular 
lactate concentration and glutamine metabolism. We observed that downregulation of 
NUDT21 significantly decreased lactate and glutamate secretion, and glutamine 
consumption similarly to the effects of CCAT2 overexpression in the same cell line (Fig. 
S6D and 5F). However these metabolic changes appeared to mirror only partly the metabolic 
effects of CCAT2 overexpression, suggesting there are additional layers of regulations 
independent of NUDT21, most likely through the bona-fide cancer metabolism modulator 
and CCAT2 target, MYC. On the other hand, the switch in GLS isoforms reflected in lower 
secretion of glutamate with the glutamine consumption remaining relatively constant, but 
had a modest effect on the extracellular levels of lactate (Fig. 5G and S6E). These findings 
suggested that GLS is not the only contributor to CCAT2 induced metabolic profile. We 
hypothesized that other metabolic targets might be regulated by CCAT2 via the same 
mechanism and thus, we performed Affymetrix HTA 2.0 array to compare the whole 
transcriptome splicing pattern in HCT116 CCAT2-overexpressing G- and T-allele cells. 
Pathway analysis revealed that several genes associated with two major metabolic pathways, 
‘Metabolism of Carbohydrates’ and ‘Fructose and Mannose Metabolism’, are significantly 
spliced between the CCAT2 G- and T-alleles (Table S4). Moreover, validating our previous 
results, we identified for GLS a negative splicing index (SI=−1.19) for the exclusion 
junction connecting exon 14 and exon 15, suggesting higher signal for the exclusion junction 
in the T-allele expressing cells. This translates into less GAC being spliced in the T-allele 
cells compared to the G-allele cells, supportive of our findings (Fig. S6F).
Collectively, these data demonstrate that GAC adds to the CRC phenotype; however it is not 
solely responsible for the metabolic phenotype observed in cells overexpressing CCAT2.
CCAT2 – CFIm – GLS regulation axis in CRC tumors
We continued with evaluating the expression pattern of CCAT2, GLS, NUDT21 and CPSF6 
in colon tumors by analyzing the publicly available TCGA database of colon cancer (http://
cancergenome.nih.gov/). We first compared 18 normal samples to 193 tumor samples and 
identified an enrichment of the GAC isoform, as well as NUDT21 and CPSF6 in tumor 
tissue, whereas KGA showed the opposite pattern (Fig. 6A, 6B, 6C and 6D). We further 
analyzed the associations between CCAT2, NUDT21, CPSF6, GAC and KGA in the TCGA 
dataset of colon cancer samples (2012) and detected a direct correlations of CCAT2, CPSF6, 
NUDT21 with GAC (rs= 0.26, P=0.0006; rs= 0.68, P<0.0001 and rs= 0.72, P<0.0001, 
respectively, Fig. S7A) and inverse correlations between CCAT2, CPSF6, NUDT21 and 
KGA (rs= −0.17, P=0.0271; rs= −0.47, P<0.0001 and rs= −0.60, P<0.0001, Fig. S7A), as 
well as between KGA and GAC (rs= −0.590, P<0.0001) (Fig. S7A). We also obtained 
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significant direct associations of CCAT2 with CPSF6 and NUDT21 (rs= 0.20, P=0.0082 and 
rs= 0.26, P=0.0007, Fig. S7A). We did not find any significant correlations between the 
expression of MYC and NUDT21, GAC or KGA. Since our in vitro findings advanced the 
concept that CCAT2 G-allele is promoting the expression of GAC, we compared the levels 
of GAC and KGA between patients having GG, GT and TT genotype. We observed a 
significant association with the genotypes for GAC, having the highest expression in patients 
with GG genotype, but not for KGA (Fig. 6E and S7B). Similarly, we did not find any 
association of NUDT21 or MYC with the genotypes (Fig. S7C and S7D). These results 
suggested the molecular mechanism uncovered in vitro is present in CRC patients. 
Moreover, we analyzed the correlation between the expression of the two isoforms and the 
overall survival of patients from the TCGA dataset and observed a significant association of 
high GAC expression combined with low KGA expression with shorter overall survival (Fig. 
S7E). This suggested that the GAC isoform may accelerate the progression of cancer. In 
addition, we interrogated the TCGA colon cancer dataset for genes that significantly 
correlate with the lncRNA and performed Gene Set Enrichment Analysis (GSEA) and 
Ingenuity Pathway Analysis (IPA - Qiagen) to identify the CCAT2 gene signatures. Various 
metabolically relevant pathways were found significantly associated with CCAT2 expression 
by both analyses (Fig. 7A and 7B). We further inquired whether the genes that were found 
significantly correlated with CCAT2 expression were also associated with the genotypes of 
rs6983267 SNP. We repeated the GSEA analysis and screened for pathways that correlated 
with either of the genotypes (FDR q-val<0.25 and Nominal P-val<0.05). We identified 
various metabolic and RNA processing pathways that were associated with certain 
genotypes (Fig. 7C). Interestingly, several of the pathways were related with the ones 
identified by the Affymetrix HTA 2.0 array (highlighted in green in Fig. 7C), suggesting that 
CCAT2 may modulate cellular metabolism in CRC patients through a network of metabolic 
genes regulated most likely via the same mechanism of alternative splicing (see Table S4).
To assess the protein expression of CFIm68, CFIm25, GAC and KGA, we performed 
Western blot analysis on paired normal mucosae and CRC samples (Patient Cohort #1) and 
identified same high protein levels of CFIm25 and GAC in tumor tissue compared to normal 
mucosae for 61.5% (8/13) of the pairs (Fig. 6F). As for the KGA isoform, protein levels 
were mostly lower in tumor samples or comparable to the levels in normal samples (Fig. 
6F). The 68 kDa subunit of the CFIm complex was either very low or not expressed in 
approximately half of the paired samples (7/13), while in the rest of the pairs it was clearly 
overexpressed in tumors (Fig. S7F). We also measured CCAT2 expression by RT-qPCR in 
the same set of samples and confirmed a positive correlation between CCAT2, CFIm25 and 
GAC for 69.2% of the samples (Fig. 6F, 6G, S7G and S7H). Moreover, the samples that had 
elevated levels of CCAT2 displayed a high GAC/KGA ratio (GAC/KGA=2–5.7) (Fig. S7I). 
We repeated the measurements in a second set of paired normal mucosae and CRC samples 
(Patient Cohort #2) and obtained similar results (Fig. S7J and S7K). Both CFIm25 and GAC 
proteins were overexpressed in 60% (3/5) of tumor samples. In all samples, elevated protein 
levels of CFIm25 and GAC matched the increased RNA levels of CCAT2. Additionally, we 
have genotyped the tumors from Patient Cohort #1 and found that the association of GG 
genotype with higher GAC and CFIm25 protein expression (samples marked in red) was 
consistent for 75% of patients (3/4), while for the GT genotype the association was present 
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only in 62.5% of patients (5/8) (Fig. 6G). No conclusion can be drawn for the TT genotype 
due to the limited representation of the genotype in this cohort (one patient). Altogether, this 
mechanism of GLS regulation was detected in the majority of the analyzed CRC cases 
(61%, 11/18).
DISCUSSION
Our study demonstrates that the rs6983267 SNP (G/T) induces changes in the secondary 
structure of the lncRNA, CCAT2, initiating a domino effect mechanism, which leads to 
allele-specific reprograming of cellular energy metabolism. The consequence of the allele-
specific interaction between CCAT2, CFIm and GLS pre-mRNA appears to be the selection 
of the poly(A) site within intron 14 of GLS, resulting in the preferential splicing to the GAC 
isoform, the more catalytically active of the two GLS isoforms (Cassago et al., 2012). 
Although a recent study has described the negative regulation of GLS by CFIm25 in 
glioblastoma via 3′UTR processing mechanisms (Masamha et al., 2014), suggesting a 
tumor-suppressive role for CFIm25, in our model, neither of the GLS isoforms is subjected 
to 3′UTR shortening (data not shown). In the context of these findings and considering that 
CCAT2 is not expressed in glioblastoma (data not shown), our results reveal an intriguing 
aspect of lncRNA mechanism of action, namely the ability of a lncRNA to alter the function 
of the partner RNA-binding protein/complex. The enrichment on metabolites related to TCA 
cycle that we observed for tumors derived from HCT116 cell overexpressing CCAT2 G-
allele are supported by Kaldma and colleagues’ findings describing that CRC tumors are not 
purely glycolytic, but rather dependent on OXPHOS for ATP production (Kaldma et al., 
2014).
The aberrant expression of GLS has been reported in many types of cancer, including CRC 
(Huang et al., 2014) Furthermore, various studies have described GAC as the more abundant 
isoform in lung adenocarcinoma, head and neck squamous cell carcinoma, kidney renal clear 
cell carcinoma and AML (Jacque et al., 2015; van den Heuvel et al., 2012; Xia et al., 2014). 
Glutamine metabolism has also been associated with genomic instability (Jeong et al., 
2013), commonly encountered in CRC and previously shown to be promoted by CCAT2 
(Ling et al., 2013b), and appears to be endorsed by the G risk allele. However, it must be 
stated that CCAT2 is modulating energy metabolism in a general fashion via MYC and in an 
allele-specific manner via GLS and other metabolic enzymes and/or metabolites, whose 
expression is finely regulated by the interaction of CCAT2 with CFIm. Although the 
differences in regulation between the G- and T-alleles may not be impressive, the variation 
in expression of multiple enzymes/metabolites may have an additive effect towards a clear 
phenotypical change. The complex mechanism presented in this manuscript encompassing 
lncRNA, protein complexes, oncogenes and transcription factors, opens several windows for 
targeted therapy. The metabolic enzyme GLS is already considered a therapeutic target for 
cancer (Vander Heiden, 2011); however, our work introduces the opportunity of targeting in 
particular the cancer-specific GAC isoform.
We reveal also the complexity and refinement of the interaction networks among the alleles 
of a non-coding RNA, the components of a protein complex and the splicing isoforms of a 
metabolic enzyme that contribute to the malignant transformation and progression of CRC.
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EXPERIMENTAL PROCEDURES
Full details of Experimental Procedures are presented in Supplementary Experimental 
Procedures section.
Glucose uptake assay
Cells were plated in 96 well plates (25,000 cells/well) 16 h before performing the assay. The 
medium was removed and cells were washed twice with PBS. To the wells containing the 
blanks 50 μl PBS was added, while for the wells with the samples 50 μl 2-NBDG (100 μM) 
(Sigma) was added and the mixture was incubated 10 min at 37°C and 5% CO2. After 
incubation, cells were washed twice with ice-cold PBS to stop the reaction and 200 ul PBS 
was added to each well. Fluorescence measurements were performed at 485/520 nm with the 
PHERAstar FS (BMG Labtech).
Lactate production assay
To measure lactate production, cells that were 80% confluent were replenished with fresh 
medium. Aliquots of the medium were removed at the indicated time points (24 or 48 h) for 
measurement of lactate, using an Accutrend lactate analyzer (Roche). At each time point, 
cell numbers were also counted for normalization of lactate generation.
Intracellular glutamate assay
The glutamate concentration in cell lysates was measured using the Glutamate Colorimetric 
Assay kit (Biovision) and following manufacturer’s protocol. Briefly, 1 × 106 cells per 
tested sample were homogenized in 100 μl assay buffer and centrifuged to remove insoluble 
material. One hundred μl reaction mix was added to the supernatant, standards and 
background control samples and after 30 min incubation at 37°C, absorbance was measured 
at 450 nm with a SpectraMax Plus384 MicroPlate Reader (Molecular Devices). The 
experiment was performed in quadruplicate.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. CCAT2 regulates cancer metabolism in vitro and in vivo
(A) Glucose uptake, lactate production and oxygen consumption assays in HCT116 stable 
clones (E – empty control vector, OC1 and OC3 – CCAT2-overexpressing – GG genotype). 
(B) Glucose uptake, lactate production and oxygen consumption assays in KM12SM cells 
with CCAT2 downregulation (GT-genotype). (C) Whole cell lysate Glutaminase activity 
measured in HCT116 CCAT2-overexpressiong G- or T-allele and control cells. (D) Partial 
least squares discriminant analysis (sPLS-DA) of HCT116 cells stably overexpressing 
CCAT2 with either G - or T-allele, and control cells (E – empty vector) in vitro allowed an 
adequate classification of the different cell lines according to its metabolome*. (E) 
Xenograft tumors derived from the same cell lines were also correctly classified by sPLS-
DA analysis. Results are presented as normalized mean values ± SD. See also Fig. S1 and 
Table S1.
*sPLS-DA algorithm allows the classification of the samples based on the different 
abundances of each metabolite trying to find the maximum covariance between treatments 
and metabolome, in this way finding the most important metabolites for explaining the 
different effects of the treatments.
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Figure 2. CCAT2 induces the preferential splicing of GAC
(A) Western Blot analysis of GAC, KGA in HCT116 CCAT2-overexpressing (OC1 and 
OC3) and control cells. (B) RT-qPCR assessing the mRNA expression of GAC and KGA in 
HCT116 CCAT2-overexpressing cells (OC1 and OC3) and control cells. (C) Western Blot 
analysis of GAC, KGA in KM12SM cells with CCAT2 downregulation. (D) Western Blot 
analysis of GAC, KGA in HCT116 stably overexpressing CCAT2 G- or T-allele and control 
cells. (E) Fluorescence microscopy images of HCT116 stable clones (E – empty control 
vector, OC1 and OC3 – CCAT2-overexpressing) transfected with the RG6 Intron 14 vector 
and the analysis of the EGFP/dsRED ratio. (F) Fluorescence microscopy images of HCT116 
CCAT2 G-allele and T-allele transfected with the RG6 intron 14 vector and the analysis of 
the EGFP/dsRED ratio. Results are presented as normalized mean values ± SD. See also Fig. 
S2 and Table 2.
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Figure 3. CFIm protein complex binds GLS pre-mRNA
(A) Western Blot analysis of CFIm25, GAC and KGA in HCT116 OC1 and KM12SM cells 
transiently transfected with siRNA for NUDT21, GLS (targeting the coding sequence shared 
by the two isoforms) and siRNA control. (B) RT-qPCR assessing the GAC/KGA mRNA 
ratio in HCT116 CCAT2-overexpressing cells (OC1 and OC3) and control cells (E) with 
modulated CFIm25 expression (C) Western Blot analysis of GAC and KGA in HCT116 
OC1 cells with transient blockage of CFIm25 binding motifs (UGUA) by antisense 
oligonucleotides (ASOs). Schematic representation of the mechanism is presented below. 
(D) RT-qPCR assessing the fold enrichment of GLS, CCAT2, NEAT1 and GAS5 RNA 
bound to CFIm25 protein (RNA immunoprecipitation). Data are presented as fold 
enrichment ratios between control HCT116 cells (E) and CCAT2-overexpressing G- or T-
allele. RT-qPCR assessing the fold enrichment of GLS mRNA (E) and CCAT2 (F) bound to 
CFIm25 and CFIm68 in HCT116 cells CCAT2-overexpressing G- or T-allele and control 
cells (E). (G) Fluorescence microscopy images of KM12SM cells transfected with 
siNUDT21 and scr, followed by transfection with the RG6 intron 14 vector, and the analysis 
of the EGFP/dsRED ratio. Results are presented as normalized mean values ± SD. See also 
Fig. S3 and Table 2.
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Figure 4. The rs6983267 SNP afftects the interaction of CCAT2 with the CFIm protein complex
(A) Western Blot analysis of the proteins pulled down with the MS2-CCAT2 vectors (G, T, 
A, C and DEL) showing the presence of CFIm25 for the G allele and CFIm68 for the T-
allele. (B) Northern Blot analysis showing the presence of CCAT2 and intron 14 (600bp 
fragment) in the lysate pulled down with TALON resin (upper panel). Western Blot analysis 
showing the presence of the His6-tagged CFIm complex in the lysate pulled down with the 
TALON resin (lower panel). (C) Northern Blot analysis showing the presence of CCAT2 and 
intron 14 (600bp fragment) in the lysate pulled down with Streptavidin beads. Lane 1 
marked with the star symbol is identical to lane 3 in Fig. S4D. Schematic illustration of the 
interaction of CCAT2 with GLS pre-mRNA (representation is not at scale) (D) Northern 
Blot analysis showing the presence of CCAT2 and intron 14 (600bp fragment) in the lysate 
pulled down with Streptavidin beads (upper panel). Western Blot analysis showing the 
presence CFIm25, monomer (26 kDa) and dimer (64 kDa), and His6-tagged CFIm68 (38 
kDa) (lower panel). (E, F) AFM images of CCAT2:CFIm:intron 14 quaternary complex 
including either CCAT2 T-allele (E) or CCAT2 G-allele (F). See also Fig. S4, S5 and Table 
3.
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Figure 5. GLS promotes in vivo metastases and in vitro cell proliferation and migration
(A) Migration of HCT116 OC1 cells (GG genotype) treated with the inhibitor 968 and 
DMSO (left panel) and with siGLS and scrambled siRNA (right panel). (B) Migration of 
KM12SM cells (GT genotype) with stable downregulation of GAC. KM12SM shGFP cells 
represent the control cells. (C) Number of the lung micrometastases for two groups (shGFP 
– 4 mice and shGAC – 4 mice) assessed by IHC (left panel). IHC images showing 
micrometastases in the three groups and images showing the presence or absence of lung 
metastases for mice injected in the tail-vein with KM12SM shGFP and shGAC cells, 
respectively (right panel). (D, E) Growth curves for HCT116 OC1 and control cells (GG 
genotype) treated with DMSO (control) or the GLS allosteric inhibitor 968 (10 μM) (D) and 
KM12SM cells (GT genotype) with stable downregulation of GAC (E). Glutamine and 
glutamate concentration in the media relative to the empty well 24 hours after seeding 
HCT116 CCAT2-overexpressing cells (OC1 – GG genotype) transfected with siRNA against 
NUDT21 and scrambled (F) and ASOs for inhibiting the binding sites of CFIm25 (G). 
Results are presented as normalized mean values ± SD. See also Fig. S6 and Table 4.
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Figure 6. CCAT2, NUDT21 (CFIm25), CPSF6 (CFIm68) and GLS (GAC and KGA) expression 
pattern in TCGA dataset and CRC patient samples
(A, B, C and D) Analysis of NUDT21, CPSF6, GAC and KGA mRNA expression in TCGA 
RNA-Seq colon cancer sample set. (E). Association of GAC mRNA expression with the 
genotypes (GG, GT and TT) of the rs6983267 SNP for CRC patients (TCGA RNA-Seq 
dataset). (F) Western Blot analysis of CFIm25, GAC and KGA expression in paired CRC 
samples (Patient cohort #1). (G) RT-qPCR analysis for CCAT2 in the same paired CRC 
samples (Patient cohort #1). Results are presented as normalized mean values ± SD. See also 
Fig. S7.
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Figure 7. CCAT2 gene signature in colon cancer patients (TCGA dataset)
Genes associated with CCAT2 were analyzed by Gene Set Enrichment Analysis (GSEA) (A) 
and Ingenuity Pathway Analysis (IPA - Qiagen) (B). Relevant examples for each analysis are 
presented in panels (A) and (B). (C) Table containing the pathways significantly associated 
with CCAT2 expression and rs6983267 genotype (FDR q-val<0.25 and Nom p-val<0.05). 
Pathways that were positively correlated are marked with red and the ones that are 
negatively correlated are marked with blue. Highlighted in green are the pathways found 
common between GSEA analysis and the Affymetrix HTA 2.0 pathways analysis. See also 
Fig. S7 and Table S4.
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